[1]
|
C. L. Canongia, “Model of Strategic Prospection: Synergies between Competitive Intelligence (CI), Knowledge Management (KM) and Foresight (F). A Case Study of the Use of Biotechnology in Drugs for the Treatment of Breast Cancer,” Ph.D. Dissertation, Federal University of Rio de Janeiro, Rio de Janeiro, 2004.
|
[2]
|
Organization for Economic Co-Operation and Development, “Frascati Manual: Proposed Standard Practice for Surveys on Research and Experimental Development, The Measurement of Scientific and Technological Activities,” OECD Publishing, Paris, 2002.
|
[3]
|
A. L. Porter and N. C. Newman, “Patent Profiling for Competitive Advantage—Deducing Who Is Doing What, Where, and When,” In: H. F. Moed, et al., Eds., Handbook of Quantitative Science and Technology Research, Springer, The Netherlands, 2004, pp. 587-612.
|
[4]
|
World Health Organization, International Agency of Research on Cancer, “GLOBOCAN,” 2008.
http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900
|
[5]
|
Instituto Nacional de Cancer (INCA), “Tipos de Cancer,” 2013. http://www.inca.gov.br/ wps/wcm/connect/tiposdecancer/ site/home/mama
|
[6]
|
World Health Organization, International Agency of Research on Cancer, “GLOBOCAN 2008, IARC,” 2010.
http://www.who.int/mediacentre/factsheets/fs297/en
|
[7]
|
National Cancer Institute, “General Information about Breast Cancer,” 2013.
http://www.cancer. gov/cancertopics/pdq/treat ment/breast/Patient/page1
|
[8]
|
World Health Organization, “Genomics and World Health. Report of the Advisory Committee on Health Research,” 2002. http://www.who.int/en
|
[9]
|
Y. Kun and P. Tan, “Materials and Methods Relating to Breast Cancer Classification,” US Patent No. 2008193-938, 2008.
|
[10]
|
Y. Wang, J. X. Yu, Y. Jiang and F. Yang, “Laser Microdissection and Microarray Analysis of Breast Tumors Reveal Estrogen Receptor Related Genes and Pathways,” US Patent No. 2008305959, 2008.
|
[11]
|
H. Y. Chang and R. A. Gupta, “Linc RNAs in Cancer Diagnosis and Treatment,” US Patent No. 2012004278, 2012.
|
[12]
|
Y. Nakamura, T. Katagiri and S. Nakatsuru, “Method of Diagnosing Breast Cancer,” US Patent No. 2012010090, 2012.
|
[13]
|
R. M. Crooke and M. J. Graham, “Effects of Apolipoprotein B Inhibition on Gene Expression Profiles,” US Patent No. 2010331390, 2010.
|
[14]
|
Y. Paterson, P. Maciag, M. Seavey and S. Ferrone, “Compositions Comprising HMW-MAA and Fragments Thereof, and Methods of Use Thereof,” US Patent No. 200920-2587, 2009.
|
[15]
|
J. M. Cedarbaum, “Method of Administering and Using VEGF Inhibitors for the Treatment of Human Cancer,” US Patent No. 2008214465, 2008.
|
[16]
|
X. Cui, “FOXC1 Antibodies and Methods of Their Use,” US Patent No. 2012201752, 2012.
|
[17]
|
W. B. Kinlaw, “Prognosis and Treatment of Breast Cancer,” US Patent No. 2009232818, 2009.
|
[18]
|
C. Esslinger, S. Kuenzle, I. Abela, A. Zippelius, D. Jaeger, A. Knuth, R. Nitsch, H. Moch and N. Goebels, “Monoclonal Human Tumor-Specific Antibody,” US Patent No. 2010330075, 2010.
|
[19]
|
S. Chen and B. Zhu, “Nano-Scale Artificial Oil Body for Targeted Drug Delivery System Detection and Treatment,” Chinese Patent No. 102743327, 2012.
|
[20]
|
S. Y. Sun, “FK Gene, Coding Protein and Application Thereof,” Chinese Patent No. 101058604, 2007.
|
[21]
|
S. Y. Sun, “Breast Cancer Relevant P69 Gene, Coding Protein and Application Thereof,” Chinese Patent No. 10105-8808, 2007.
|
[22]
|
R. Niu, L. Zhang, D. Wang, Y. Shi, X. Wei, Y. Yang, J. Huang, Y. Niu, B. Sun and X. Hao, “Human Breast Cancer Resisting Recombination Immunotoxin M4G3/ ScFv-PE40,” Chinese Patent No. 101148475, 2008.
|
[23]
|
X. Yao, F. Wang, E. Song, H. Deng, D. Wang, J. Chen, Z. Dou and X. Ding, “Acceptor Protein, and Coding Gene and Application Thereof,” Chinese Patent No. 102475890, 2012.
|
[24]
|
S. Y. Yi, “Breast Cancer Related Gene DREE, Its Coded Protein and Uses,” Chinese Patent No. 1807455, 2006.
|
[25]
|
W. W. Jiang, “scFvC6.5-s Trail Fusion Gene and Protein, and Its Preparation,” Chinese Patent No. 1865445, 2006.
|
[26]
|
S. Wu and J. Gong, “Nucleic Acid Aptamer with High Specificity and High Affinity to Human Breast Carcinoma Tissue, Preparation Method and Application Thereof,” Chinese Patent No. 101148666, 2008.
|
[27]
|
S. Li, Y. Wang, J. Pan, Q. Zhao and H. Wang, “Humanized Breast Cancer Antigen and Antibody Thereof,” Chinese Patent No. 101962405, 2011.
|
[28]
|
Q. Wei, X. Cao, Y. Jun and Y. Lu, “Human Prolactin Receptor Antibody and Application Thereof,” Chinese Patent No. 102250244, 2011.
|
[29]
|
Y. Jiang, N. Zhang and Z. Xie, “Medicament for Curing Breast Carcinoma and Special Antisense Oligonucleotide Therefor,” Chinese Patent No. 101275134, 2008.
|
[30]
|
J. Luo, X. Wang, M. Liu, X. Tang and R. Jin, “GPR116 (G-Protein Coupled Receptor) Gene, Receptor Protein Coded by Same and Application of the GPR116 Gene,” Chinese Patent No. 102041259, 2011.
|
[31]
|
E. Song, J. Chen and X. Yao, “Application of PITPNM3 Gene in Preparing Medicine for Inhibiting Breast Cancer Invasion and Transfer,” Chinese Patent No. 102160895, 2011.
|
[32]
|
S. Yuan, Z. Shi, W. Han, Y. Zhang, R. Ling, N. Li and T. Wang, “Recombinant BCG Vaccine Based on Human MUC1 Repetitive Sequence and GM-CSF Fusion Expression,” Chinese Patent No. 101575607, 2009.
|
[33]
|
N. Guo, Z. Xie and M. Shi, “Heterogenetic Antigen-Fc Fusion Protein Capable of Inducing Antitumor Immunity of Organism and Application Thereof,” Chinese Patent No. 101638440, 2010.
|
[34]
|
Y. Liu and W. Zhang, “A Series of Recombinant AdenoAssociated Viral Vectors, Construction Methods and Uses Thereof,” Chinese Patent No. 102268458, 2011.
|
[35]
|
Z. X. Li, “Method for Coustructing shRNA Expression Carrier for Inhibiting N-Acetylglucosamine Transferase V and Its Use,” Chinese Patent No. 1936012, 2007.
|
[36]
|
W. T. Wang, “Construction of HER2/neu mRNA in Vitro Transcription Vector and Use Thereof,” Chinese Patent No. 1966684, 2007.
|
[37]
|
Y. Ge, X. Zhang, J. Zhang, L. Hou and M. Xue, “KDR siRNA and Application Thereof,” Chinese Patent No. 101215563, 2008.
|
[38]
|
J. Zhang, X. Ding, J. Zhou, S. Xiang, X. Hu and M. Han, “SiRNA for Inhibiting Human KCTD1 Gene Expression and Use Thereof in Pharmacy,” Chinese Patent No. 101481688, 2009.
|
[39]
|
M. Li, L. Jun, J. Cai, Y. Huang, J. Wu and J. Yuan, “Molecular Marker HSA-miR-374a of Breast Carcinoma and Application Thereof,” Chinese Patent No. 101633922, 2010.
|
[40]
|
J. Dong, L. Fu, D. Su, X. Wu and Z. Zhu, “Breast Cancer Related Gene C10RF64 and Application Thereof,” Chinese Patent No. 101701220, 2010.
|
[41]
|
T. Nagahata and M. Emi, “Material for Suppressing SEPT11 Gene Expression,” Japanese Patent No. 254830, 2006.
|
[42]
|
N. Goto, M. Murohashi, H. Yuya, T. Isagawa and M. Kuroda, “Test Method for Predicting Recurrence of Solid Cancer and Recurrence Prophylactic,” Japanese Patent No. 2010178650, 2010.
|
[43]
|
S. Watanabe, M. Ito, J. Imai, T. Otake, T. Fujita and Y. Sakai, “Method for Discriminating Subtype of Breast Cancer,” Japanese Patent No. 2012085554, 2012.
|
[44]
|
S. Watanabe, M. Ito, J. Imai, T. Otake, T. Fujita and Y. Sakai, “Method for Diagnosis of Breast Cancer,” Japanese Patent No. 2012085556, 2012.
|
[45]
|
T. Nagahata and M. Emi, “RA13 Gene Expression Inhibitor,” Japanese Patent No. 2005287456, 2005.
|
[46]
|
H. Nakatake and C. Nozaki, “Inhibitory Antibody against Malignant Tumor Cell Growth,” Japanese Patent No. 2005-206508, 2005.
|
[47]
|
Y. Nakamura, H. Yasuoka, M. Tsujimoto, R. Goto, Z. Totsuka, K. Momiyama, K. Kakudo and N. Takami, “Therapeutic Agent for Highly Malignant Breast Cancer,” Japanese Patent No. 2008110975, 2008.
|
[48]
|
Y. Sugimoto, S. Tsukahara and Y. Imai, “Anticancer AgentResistance Overcoming Agent,” Japanese Patent No. 2006-069910, 2006.
|
[49]
|
C. W. Kim and J. Y. Jang, “Method for Treating Breast Cancer by Decreasing the Expression of Adenine Nucleotide Translocator 2 mRNA,” Korean Patent No. 2012-0095263, 2012.
|
[50]
|
D. K. Lee and H. S. Kang, “Nucleic Acid Aptamer Capable of Specifically Binding to HER-2-Overexpressing Breast Cancer Cell or Tissue and Use Thereof,” Korean Patent No. 20110086433, 2011.
|
[51]
|
D. S. F. Young, H. P. Findlay, S. E. Hahn and L. M. Cechetto, “Cancerous Disease Modifying Antibodies,” US Patent No. 2009104115, 2009.
|
[52]
|
W. Yin, W. Xia, Y. Ma, C. Zhao, Y. Hong, J. Han and H. Chen, “Application Method for Medicament Based on NAD<+> and NADH,” Chinese Patent No. 102061285, 2011.
|
[53]
|
H. Q. Nguyen, F. Lin, X. Bi, H. J. Mcbride and S. S. Hu, “Anti-Oral Antigen Binding Proteins and Uses Thereof,” US Patent No. 2012231006, 2012.
|
[54]
|
J. Collard, O. K. Sherman, C. Coito and B. Leon, “Treatment of Sirtuin 1 (SIRT1) Related Disease by Inhibition of Natural Antisense Transcript to SIRT1,” Chinese Patent No. 102307997, 2012.
|